Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide 0.68 mg/mL vs 1.0 mg/mL
NCT04228354Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2020
- Primary completion
- Jun 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in obesity and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide plasma concentration curve from 0 to tz and Maximum semaglutide plasma concentration. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04228354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228354.